Amarin Corp Plcuk (AMRN) Cash & Equivalents (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Cash & Equivalents of $201000.0 for Q1 2026, down 33.0% year-over-year from $300000.0 in Q1 2025, and down 99.85% quarter-over-quarter from $134.7 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Cash & Equivalents (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Cash & Equivalents data on file, last reported at $201000.0 in Q1 2026.
- Cash & Equivalents for Q1 2026 came in at $201000.0, down 33.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $201000.0 (down 33.0% YoY), and the FY2025 annual result was $134.7 million, up 44786.67% from the prior year.
- Cash & Equivalents fell to $201000.0 in Q1 2026 per AMRN's latest filing, from $134.7 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $228.0 million in Q2 2022 and troughed at $201000.0 in Q1 2026.
- A 5-year average of $76.6 million and a median of $525000.0 in 2023 frame the typical range for Cash & Equivalents.
- On a YoY basis, Cash & Equivalents climbed as much as 44786.67% in 2025 and fell as far as 99.81% in 2025.
- A 5-year view of Cash & Equivalents shows it stood at $523000.0 in 2022, then advanced by 0.38% to $525000.0 in 2023, then tumbled by 42.86% to $300000.0 in 2024, then surged by 44786.67% to $134.7 million in 2025, then sank by 99.85% to $201000.0 in 2026.
- Business Quant data shows AMRN's Cash & Equivalents at $201000.0 in Q1 2026, $134.7 million in Q4 2025, and $301000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 4.64 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 5.28 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 21.69 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 9.39 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 5.33 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 7.63 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 1.70 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 9.57 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 201,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 201,000.00 |
| Dec 31, 2025 | 134.66 Mn |
| Sep 30, 2025 | 301,000.00 |
| Jun 30, 2025 | 147.90 Mn |
| Mar 31, 2025 | 300,000.00 |
| Dec 31, 2024 | 300,000.00 |
| Sep 30, 2024 | 156.90 Mn |
| Jun 30, 2024 | 215.90 Mn |
| Mar 31, 2024 | 525,000.00 |
| Dec 31, 2023 | 525,000.00 |
| Sep 30, 2023 | 524,000.00 |
| Jun 30, 2023 | 524,000.00 |
| Mar 31, 2023 | 191.41 Mn |
| Dec 31, 2022 | 523,000.00 |
| Sep 30, 2022 | 3.92 Mn |
| Jun 30, 2022 | 228.00 Mn |
| Mar 31, 2022 | 219.20 Mn |
| Dec 31, 2021 | 219.45 Mn |
| Sep 30, 2021 | 222.90 Mn |
| Jun 30, 2021 | 3.92 Mn |